Ginkgo Bioworks Holdings, Inc. DNA · NYSE
$9.82 +1.13% (+$0.11)
Summary
31 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 29% a year over the last 3 years.
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it fell by 29% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $290.8M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 3
- Sell 4
Today's price within the analysts' price targets
The average target of $5 is 49% below today's price. 36% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Service 100%
By region
The company reports no revenue by region.
Service brings in 100% of revenue.
Segments in detail